EXOZ vs GEVO vs LNZA vs MCRB vs CODX

For growth investors, Gevo, Inc.

(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus -84. 1% for Co-Diagnostics, Inc. (CODX). Seres Therapeutics, Inc. (MCRB) offers the better valuation at 12. 1x trailing P/E, making it the more compelling value choice. Analysts rate Gevo, Inc. (GEVO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, eXoZymes, Inc.

(EXOZ) delivered a total return of +15. 6%, compared to -98. 1% for Seres Therapeutics, Inc. (MCRB). Over 10 years, the gap is even starker: EXOZ returned +11. 2% versus GEVO's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), eXoZymes, Inc.

(EXOZ) is the lower-risk stock at 0. 92β versus Seres Therapeutics, Inc. 's 1. 73β — meaning MCRB is approximately 87% more volatile than EXOZ relative to the S&P 500. On balance sheet safety, Co-Diagnostics, Inc. (CODX) carries a lower debt/equity ratio of 6% versus 6% for LanzaTech Global, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Gevo, Inc.

(GEVO) is pulling ahead at 849. 3% versus -84. 1% for Co-Diagnostics, Inc. (CODX). On earnings-per-share growth, the picture is similar: Seres Therapeutics, Inc. grew EPS 103. 4% year-over-year, compared to -188. 0% for eXoZymes, Inc.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Seres Therapeutics, Inc.

(MCRB) is the more profitable company, earning 721. 9% net margin versus -75. 3% for Co-Diagnostics, Inc. — meaning it keeps 721. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXOZ leads at 0. 0% versus -119. 1% for MCRB. At the gross margin level — before operating expenses — CODX leads at 64. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, eXoZymes, Inc.

(EXOZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92)). Seres Therapeutics, Inc. (MCRB) carries a higher beta of 1. 73 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXOZ: +11. 2%, MCRB: -98. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EXOZ (Healthcare) and GEVO (Basic Materials) and LNZA (Industrials) and MCRB (Healthcare) and CODX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EXOZ is a small-cap quality compounder stock; GEVO is a small-cap high-growth stock; LNZA is a small-cap quality compounder stock; MCRB is a small-cap deep-value stock; CODX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.